We have had a number of productive collaborations with pharmaceutical companies, including Foundation Medicine. This study was the largest analysis of metastatic ILC at that point in time, and showed that mILC had an enrichment of NF1 mutations, and higher TMB (with APOBEC signature) compared to NST. Assessing sites of metastatic specimens showed fewer metastases in the liver and enrichment in reproductive sites, GI tract, omentum and bone marrow.
Important ILC Research: “Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer”
